Monday said Phase 3 TEMPO-2 study evaluating tavapadon in early Parkinson's disease met its primary goal. In the ...
Nov. 12, 2024 — Researchers have identified a potential biomarker of Parkinson's disease progression. According to the new study, patients with a slow progression of ... Oct. 8, 2024 ...
A study from the University of Arizona shows that the protein PNA5 helps protect brain cells, offering a promising avenue for treating cognitive symptoms in Parkinson’s disease, a condition currently ...
BioArctic has dosed the first subject with the monoclonal antibody, exidavnemab, in the randomised Phase IIa EXIdavnemab ...
Investigators led by Tanya Simuni, MD, the Arthur C. Nielsen, Jr., Research Professor of Parkinson's Disease and Movement ...
The company is hoping to show GT-02287 can slow Parkinson's progression by restoring function of GCase, an enzyme encoded by ...
Yasir Gallero-Salas discusses quantifying alpha-synuclein spread and dopaminergic neuron loss in a model of Parkinson’s using ...
BioArctic begins patient dosing in EXIST phase 2a study in Parkinson’s disease: Stockholm Saturday, December 7, 2024, 18:00 Hrs [IST] BioArctic AB (publ), a Swedish research-bas ...
Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...
Wearable devices once seemed futuristic for Parkinson’s disease. Today, tools like activity trackers, tremor gloves, and ...
BIIB122, previously known as DNL151, is a small molecule designed to inhibit LRRK2, mutations in which are the most common cause of inherited Parkinson's.